Analysis of trend in the role of national and regional hubs in prostatectomy after prostate cancer diagnosis in the past 5 years: A nationwide population-based study
- Author:
Seong Cheol KIM
1
;
Seungbong HAN
;
Ji Hyung YOON
;
Sungchan PARK
;
Kyung Hyun MOON
;
Sang Hyeon CHEON
;
Gyung-Min PARK
;
Taekmin KWON
Author Information
- Publication Type:Original Article
- From: Investigative and Clinical Urology 2024;65(2):124-131
- CountryRepublic of Korea
- Language:English
-
Abstract:
Purpose:The regions where patients diagnosed with prostate cancer by biopsy receive prostatectomy are divided into national hub and regional hubs, and to confirm the change in the role of regional hubs compared to national hub.
Materials and Methods:Data from July 2013 to June 2017 encompassing 218,155 patients aged ≥18 years diagnosed with prostate cancer were analyzed using the Health Insurance Review & Assessment Service database. The degree of patient outflow was assessed by dividing the regional diagnosis-to-surgery ratio with the national ratio for each year. Based on this ratio, national and regional hubs were determined.
Results:Seoul consistently maintained a patient influx with a ratio above 1.6. Busan and Gyeonggi consistently exceeded 0.9, while Ulsan and Daegu steadily increased, exceeding 1.0 between 2015 and 2016. Jeonnam province also consistently maintained the ratio above 0.7. Jeju, Daejeon, Gangwon, and Incheon remained below 0.5, indicative of substantial patient outflows, whereas Gwangju and Gyeongbuk had the highest patient outflows with ratios below 0.15. Therefore, Seoul was designated as a national hub, whereas Busan, Gyeonggi, Ulsan, Daegu, and Jeonnam were classified as regional hubs. Jeju, Daejeon, Gangwon, and Incheon were the dominant outflow areas, while Gwangju and Gyeongbuk were the highest outflow areas.
Conclusions:Seoul, as the national hub for prostate cancer surgery, operated on 1.76 times more patients than any other region during 2013–2017. Busan, Gyeonggi, Ulsan, Daegu, and Jeonnam functioned as regional hubs, but approximately 10%–20% of patients sought treatment at national hubs.
